|
|||||
|
|
PTK/ZK (Novartis) |
|
| Authors: | Drevs Joachim |
| Affiliation: | Institute of Molecular Oncology, Department of Medical Oncology, Tumor Biology Center, Breisacher Strasse 117, 79106 Freiburg, Germany. drevs@tumorbio.uni-freiburg.de |
| Abstract: | PTK/ZK, a VEGF receptor tyrosine kinase inhibitor, is under development by Novartis AG and Schering AG as an inhibitor of angiogenesis for the potential treatment of various cancers. |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ | |